Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…
The drug market for chronic spontaneous urticaria (CSU; previously known as chronic idiopathic urticaria) is dominated by oral medications, including those approved (e.g., first- and second-…
Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging therapies…
The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4/6 inhibitors (…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…